The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

开始日期2025-09-01

申办/合作机构

NYU Langone Health

NCT05960578

/ Recruiting临床2期IIT

TRAMP: Tumor Necrosis Factor- α Blockade and AR Inhibition in Men With CRPC

This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving golimumab and apalutamide may work better in treating patients with castration-resistant prostate cancer.

开始日期2024-05-23

申办/合作机构

University of Washington

[+1]

NCT05242484

/ Active, not recruiting临床2期

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.

开始日期2022-09-19

申办/合作机构

Janssen Research & Development LLC

100 项与戈利木单抗相关的临床结果

登录后查看更多信息

100 项与戈利木单抗相关的转化医学

登录后查看更多信息

100 项与戈利木单抗相关的专利（医药）

登录后查看更多信息

1,724

项与戈利木单抗相关的文献（医药）

2025-10-01·JOURNAL OF NEUROIMMUNOLOGY

When gut and nerves collide: A case of Neuromyelitis Optica Spectrum disorder after golimumab for ulcerative colitis

Article

作者: Sucupira, Josemary Cavalcante Lemos ; Moraes, Bernardo de Faria ; Leite, Gustavo André Pedral Diniz ; Leite, Gabriel André Pedral Diniz ; Junior, Marcus Gualberto de Oliveira ; Cançado, Guilherme Grossi Lopes

Anti-TNF alpha agents, such as golimumab, are effective treatment options for moderate to severe inflammatory bowel disease. However, demyelinating syndromes have been reported as rare adverse events. We present the first documented case of Neuromyelitis Optica Spectrum Disorder with positive aquaporin-4 antibodies following golimumab therapy for ulcerative colitis, manifesting as intractable hiccups secondary to Area Postrema Syndrome. The patient was treated with plasmapheresis and rituximab, with partial improvement.

2025-09-01·Lancet Rheumatology

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial

Article

作者: Dubash, Sayam R ; De Marco, Gabriele ; Sultan, Shabina ; Hensor, Elizabeth M A ; Tan, Ai Lyn ; Marzo-Ortega, Helena ; Helliwell, Philip S ; McGonagle, Dennis ; Emery, Paul ; Michelena, Xabier ; Coates, Laura C

BACKGROUND:

The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.

METHODS:

We did a double-blind, randomised, placebo-controlled, parallel-group, single-centre study in adults with treatment-naïve active psoriatic arthritis. Participants were required to have been diagnosed up to 24 months before enrolment and had to be naïve to conventional synthetic, biologic, or targeted synthetic disease-modifying antirheumatic drugs or systemic treatments before enrolment. Participants were randomly assigned (1:1) to receive either combination therapy of golimumab and methotrexate or placebo and methotrexate, stratified by the number of involved peripheral joints at baseline. Investigators and participants were masked to treatment allocation. At baseline, all participants received methylprednisolone (120 mg intramuscular administration, single dose) and commenced weekly methotrexate (increased to 25 mg within 28 days). Golimumab or placebo were administered by subcutaneous injections every 4 weeks. By week 24, additional methylprednisolone was permitted once (totalling up to 240 mg exposure). The primary endpoint was the difference in mean Psoriatic Arthritis Disease Activity Score (PASDAS) at week 24 in the intention-to-treat population, compared using analysis of covariance via multiple linear regression. People with lived experience of psoriatic arthritis were involved in the design and conduct the study. The study was registered with EudraCT, 2013-004122-28, and is complete.

FINDINGS:

Between Nov 3, 2015 and Jan 26, 2022, 106 people were assessed for eligibility, 22 were excluded, and 84 were randomly assigned (43 to the golimumab and methotrexate group and 41 to the placebo and methotrexate group). 46 (55%) participants were male and 38 (45%) were female. The mean age was 42·5 years (SD 12·4) and 61 (73%) participants were White and seven (8%) were from any Asian, Black, or other ethnic background. PASDAS did not differ between treatment groups at week 24 (unadjusted mean 3·09 [SD 1·32] in the placebo and methotrexate group and 2·70 [1·38] in the golimumab and methotrexate group; adjusted difference -0·55 [95% CI -1·12 to 0·03]; p=0·064). More participants in the placebo and methotrexate group received additional corticosteroids before week 24 (20 [49%] of 41 vs nine [21%] of 43; odds ratio 0·28 [95% CI 0·11 to 0·72]; p=0·009). Similar numbers of participants had adverse events (38 [93%] of 41 in the placebo and methotrexate group vs 41 [95%] of 43 in the golimumab and methotrexate group; risk difference 0·03 [95% CI -0·09 to 0·15]), although altered laboratory investigations and infections occurred more frequently in the golimumab and methotrexate group. No deaths, serious, or unexpected adverse events occurred.

INTERPRETATION:

Both interventions led to improved disease activity in patients with early, untreated psoriatic arthritis, without a clinically or statistically significant difference in PASDAS between treatment groups at week 24. Participants in the placebo and methotrexate group required more rescue corticosteroids. Sustained results were observed at week 52 in both groups, without serious or unexpected adverse events.

FUNDING:

Janssen Biologics BV.

2025-09-01·Applied Health Economics and Health Policy

Aggregate Distributional Cost-Effectiveness Analysis of Biologics for the Treatment of Ankylosing Spondylitis in Chile

Article

作者: Jana-Valencia, Nicolas ; Walbaum, Magdalena

BACKGROUND AND OBJECTIVE:

Ankylosing spondylitis is a complex rheumatic disease, characterised by chronic and progressive inflammation of the spine, causing an important health and economic burden for the person with the condition. Evidence shows the unequal impact of the disease in different groups of people, with a higher burden for lower socioeconomic groups. The objective of this study is to evaluate the impact of the use of biologics for the treatment of ankylosing spondylitis on health inequities in Chile.

METHODS:

We conducted an aggregate distributional cost-effectiveness analysis. Data on health outcomes and costs were derived from a cost-effectiveness model of secukinumab, etanercept, certolizumab pegol, infliximab, adalimumab and golimumab versus treatment as usual for the treatment of ankylosing spondylitis from the Chilean healthcare system perspective. Health gains and health opportunity costs were distributed across socioeconomic subgroups. Health and equity impacts, measured using the Atkinson index, were assessed on an equity-efficiency impact plane.

RESULTS:

All treatments had a positive impact on equity relative to treatment as usual. At an opportunity cost threshold of 1 Gross Domestic Product per capita/quality-adjusted life-year, secukinumab improved societal welfare irrespective of the Atkinson index value. When varying thresholds (2 and 3 Gross Domestic Product), all assessed technologies contributed to an increase in societal welfare, regardless of the Atkinson index.

CONCLUSIONS:

Biologic treatment for ankylosing spondylitis, such as secukinumab, may reduce health inequity in the Chilean population. An aggregate distributional cost-effectiveness analysis framework is feasible to implement alongside a cost-effectiveness analysis in the context of the Chilean healthcare system to provide additional information of equity impacts for health technology assessment recommendations and policy making.

225

项与戈利木单抗相关的新闻（医药）

2025-09-08

·靶点圈

从实验室到临床：TNF/TNFR 超家族药物研发的传奇之路（综述大盘点）

01 TNF和TNFR超家族的生物学基础家族组成肿瘤坏死因子(TNF)和肿瘤坏死因子受体(TNFR)在免疫细胞的促炎和凋亡信号传导中起关键作用，其信号失调与多种疾病相关。TNF超家族(TNFSF)含18个人类基因，编码20多种蛋白(包括异源三聚体)，与29种TNF受体超家族(TNFRSF)成员通过40多种配体-受体相互作用模式进行信号传递。 ● TNF超家族的结构特征：TNFSF成员以肿瘤坏死因子同源结构域为支架，通过原体组装形成同源/异源三聚体(发挥功能的受体结合单位)。TNFSF的三聚体结构具有三个受体结合位点(由两个相邻亚基构成)，可诱导受体聚集。当配体与受体结合后，受体胞质域排列形成信号复合物，招募衔接蛋白。 ● TNFR超家族的结构特征：TNFRSF成员多是由多个二硫键构成受体胞外域的细长梯状结构，还含有半胱氨酸富集域(CRDs)，构成配体结合部分，不同成员的CRDs数量不同(1-6个)。多数TNFRSF成员发挥生物活性需要多个三聚体复合物以晶格状排列聚集。部分TNFRSF成员含有前配体组装域(PLAD)，可限制未结合配体的受体取向以防止自发激活，还可能有助于受体信号单元的多聚化。信号机制 ● 促存活通路：依赖含E3泛素连接酶的TNFR相关因子(TRAF)衔接蛋白，招募形成cIAP-TRAF-E3泛素连接酶复合物，降解抑制剂并释放活性丝氨酸激酶(如NIK、IKKα、IKKβ)，激活NF-κB、MAPK等通路，调控细胞增殖与存活。 ● 促凋亡通路：依赖死亡结构域(DD)衔接蛋白(如Fas相关死亡域)，启动胱天蛋白酶水解级联反应，诱导凋亡、坏死性凋亡并释放炎症细胞因子(如IL-1β)。图1 T细胞上的共刺激TNFRSF成员以及它们的配体和代表性信号通路生理与病理作用 ● 生理作用：参与先天性和适应性免疫系统的发育与协调，对免疫细胞的发育、活化、增殖、存活等过程起着重要调控作用，如T细胞活化、B细胞存活、淋巴器官形成等。 ● 病理作用：异常激活可能会导致炎症、癌症和自身免疫疾病等，表现为免疫活性失控，如抗原呈递细胞(APCs)、T细胞和B细胞的反应过度，以及TNFSF的过量产生作用于组织细胞直接驱动病理过程。同时，由于其在调控先天性和适应性免疫中的核心作用，TNFRSF的激活可能增强癌症中的免疫保护相关的免疫应答。图2 TNFSF成员在不同APC子集上的上下文相关角色 02 TNF/TNFR超家族的分子机制 TNF信号轴 ● 机制：TNF可由多种细胞在炎症条件下产生，通过TNFR1和TNFR2发挥作用。 ①TNFR1：广泛表达，激活后能诱导细胞死亡、免疫细胞激活及多种炎症相关分子表达，还可通过引发细胞死亡间接促进炎症； ②TNFR2：主要在特定细胞表达，其激活可促进T/B淋巴细胞增殖、存活和分化，在Tregs中与免疫耐受和抗炎功能相关。 ● 疾病关联：TNF在先天和体液免疫反应中不可或缺，但慢性炎症中其异常表达是多种IMIDs的病理标志，如类风湿关节炎(RA)、炎症性肠病(IBD)患者血清及病变组织中TNF水平升高与疾病严重程度相关，TNFRSF1A基因多态性与银屑病、溃疡性结肠炎(UC)和克罗恩病(CD)有关。 TL1A信号轴 ● 机制：TL1A作为一种炎症细胞因子，主要由树突状细胞、巨噬细胞等抗原呈递细胞在炎症刺激下表达，通过与DR3结合激活NF-κB、PI3K等通路，促进T细胞效应功能和纤维化相关细胞因子分泌，引发炎症和细胞凋亡。同时，它还存在可溶性DcR3作为诱饵受体调节其功能。 ● 疾病关联：TL1A-DR3相互作用在T细胞中起共刺激信号作用，与多种自身免疫性疾病发病机制相关。在UC和CD患者中，其血清和肠道组织中的表达水平升高，还可通过多种途径促进炎症、纤维化及组织重塑。此外，TNFSF15基因多态性与IBD、银屑病等相关。 CD40/CD40L信号轴 ● 机制：CD40在多种免疫细胞如B细胞、树突状细胞、单核细胞等表面表达；CD40L是其天然三聚体配体，主要在活化T细胞、血小板等细胞上表达。二者结合后，CD40胞内结构域募集TRAF，激活NF-κB、MAPK、Jak3/STAT3和PI3K/Akt等信号通路，促进细胞活化、增殖、分化，释放细胞因子和炎症介质，参与免疫应答和炎症反应。 ● 疾病关联：CD40/CD40L信号与多种自身免疫性疾病相关，其基因多态性与多种疾病关联。在RA、系统性红斑狼疮(SLE)和IBD患者中，其表达水平异常，阻断该信号可缓解疾病症状。 OX40/OX40L信号轴 ● 机制：OX40在激活的CD4+和CD8+T细胞上表达；OX40L在APCs等细胞上表达。二者结合后，能激活NF-κB、ERK、PI3K、AKT等信号通路，促进T细胞存活、增殖，以及IL-2、IL-4、IL-5、IL-17、IFN-γ等细胞因子的分泌，同时抑制CTLA-4等免疫抑制受体，提升免疫应答。此外，OX40信号在Tregs中会损害其抑制功能。 ● 疾病关联：OX40的基因多态性(TNFSF4)与多种IMIDs相关，在SLE、银屑病和特应性皮炎(AD)、哮喘等疾病中，OX40/OX40L的表达异常，阻断该信号在疾病治疗方面展现出潜力。 BAFF/BAFF-R信号轴 ●机制：BAFF由多种免疫细胞产生，与BAFF-R等受体结合，促进B细胞存活、成熟和抗体产生，通过非经典NF-κB信号通路传导信号。 ● 疾病关联：BAFF/BAFF-R信号在RA和SLE等自身免疫性疾病的发病和进展中起关键作用，如在这些疾病患者中，BAFF或BAFF-R的表达水平升高，与疾病活动度和病理变化相关。图3 焦点TNF/TNFR分子的分子信号机制及其拮抗作用的抗炎益处表1 TNF/TNFR超家族基因在焦点炎症性疾病中的代表性GWAS关联 03 靶向TNF/TNFR的药物研发进展 TNF拮抗剂 ● 作用机制：通过中和TNF或阻断其与TNFR1/TNFR2的结合，抑制下游炎症信号(如NF-κB通路)，减少免疫细胞过度活化和细胞因子释放。 ● 已获批的TNF拮抗剂 ①英夫利昔单抗(Infliximab，Remicade，1998年获批)：首个抗TNF单克隆抗体，是人类化IgG1单克隆抗体，获批用于CD、银屑病、RA、UC。 ②阿达木单抗(Adalimumab，Humira)：为人类IgG1单克隆抗体，通过拮抗TNF发挥作用，已获批用于CD、银屑病、RA、UC等多种IMIDs。 ③依那西普(Etanercept，Enbrel)：由人TNFR2的胞外域与人类IgG1抗体的Fc部分融合而成，可拮抗TNF，获批用于银屑病和RA。 ④戈利木单抗(Golimumab，Simponi)：是人类IgG1单克隆抗体，获批用于UC、RA，同时在CD的Ⅱ期临床试验中开展研究。 ⑤赛妥珠单抗聚乙二醇(Certolizumabpegol，Cimzia)：是聚乙二醇化的人源化IgG1单克隆抗体的抗TNF的F(ab)片段，已获批用于CD、银屑病、RA，且在UC的Ⅱ期临床试验中进行研究。 ⑥奥扎利珠单抗(Ozoralizumab，Nanozora)：为人类化三价双特异性纳米抗体，由两个抗TNF-α的VHH和一个抗HSA的VHH组成，已在日本获批用于RA。图4 TNF抑制剂的结构和FDA批准时间表 ●处于研发阶段的TNF拮抗剂 ①ABBV-3373：是一种阿达木单抗-GRM类固醇偶联物(ADC)，具有TNF拮抗和糖皮质激素受体调节双重作用，目前处于Ⅱ期临床试验阶段，用于治疗RA。 ②SAR441566：属于小分子TNF拮抗剂，处于Ⅱ期临床试验，用于RA和银屑病的治疗。其作用机制是稳定可溶性TNF三聚体的不对称构象，使其仅能结合三个可能的TNFR1受体结合位点中的两个，从而限制受体聚集和信号传导，在胶原诱导关节炎的小鼠模型中，展现出剂量依赖性的疾病症状抑制作用。 ● TNF拮抗剂的临床应用与挑战自首次获批25年多以来，TNF抑制剂一直是控制RA、IBD和银屑病等疾病最广泛使用且成功的抗炎疗法之一，能显著降低类风湿关节炎的关节炎症、银屑病的皮肤损伤及克罗恩病的肠道炎症，改善患者生活质量。但当前的TNF拮抗剂存在一些局限性，如原发性无应答率较高，在CD患者中，抗TNF治疗初始诱导的原发性无应答率在试验中为20%-40%，且在抗TNF治疗开始后的12个月内，23%-46%的患者会出现应答丢失，7%-25%的患者会停止治疗；还可能增加机会性感染风险、引发免疫原性导致抗药抗体形成和疗效逐渐丧失，以及诱发自身抗体等。这些局限性也推动着新型TNF拮抗剂的研发。 TL1A拮抗剂 ● 作用机制：TL1A拮抗剂通过阻断TL1A与DR3的相互作用，抑制相关信号通路的激活，从而减少炎症细胞因子的分泌，减轻炎症反应，并可能抑制纤维化进程。比如在肠道炎症中，可降低促炎细胞因子如TNF、IFN-γ的产生，缓解肠道炎症，还能减少成纤维细胞的活化，抑制胶原合成，改善肠纤维化。 ● 研发进展全球处于临床阶段的TL1A靶点药物有12款，其中单靶点药物9款。处于临床II期的有辉瑞的RG6631(PF-06480605/RVT-3101)、默沙东的Tulisokibart(MK-7240/PRA-023)、梯瓦制药的TEV-48574。 ①Tulisokibart(PRA023)：为一种人源化IgG1抗TL1A单抗。在克罗恩病(CD)的Ⅱa期试验中，临床缓解率为49%，内镜应答率26%，目前已启动UC的Ⅲ期试验。 ②TEV-48574：属于人IgG1抗TL1A单抗，已启动UC和CD的2期试验招募，但此前其哮喘2期研究因未达主要目标而终止。 ③PF-06480605(RVT-3101)：抗TL1A单克隆抗体，在溃疡性结肠炎(UC)的Ⅱb期试验中，14周临床缓解率达32%，显著高于安慰剂(12%)，且能降低肠道纤维化相关标志物表达。 ● 临床意义炎症性肠病(IBD)影响全球约600-800万人，美国约200万人，现有疗法仅有10-15%的患者病情缓解。TL1A拮抗剂为IBD患者提供了新的治疗选择。此外，TL1A拮抗剂还可能对其他免疫和纤维化疾病，如类风湿关节炎、特应性皮炎、系统性红斑狼疮、哮喘、银屑病等有治疗潜力。 ● 市场前景 IBD药物市场规模较大且呈增长趋势，2021年美国IBD药物市场约为150亿美元。TL1A靶点药物受到众多制药巨头青睐，如辉瑞、罗氏、默沙东、赛诺菲等纷纷布局。罗氏以高额价格收购RVT-3101，默沙东收购Prometheus-Biosciences获得PRA023，赛诺菲与梯瓦合作开发TEV-48574，这一系列动作显示出TL1A拮抗剂在未来医药市场具有较大的发展潜力。 CD40/CD40L拮抗剂 ● 作用机制：CD40L在活化T细胞上表达，与APCs表面的CD40结合后促进免疫细胞活化。靶向药物通过阻断该相互作用，抑制过度免疫反应。 ● 研发进展 ①达匹利珠单抗(Dapirolizumabpegol)：一种聚乙二醇化的抗CD40LF(ab’)片段，用于治疗SLE，在早期临床试验中显示出良好疗效，目前正在进行3期试验。 ②Frexalimab：一种新型抗CD40L单克隆抗体，能阻断CD40/CD40L细胞通路，且不会导致淋巴细胞耗竭。在治疗MS的2期试验中取得积极结果，显著减缓了复发性MS患者的疾病活动，目前已启动3期临床试验，同时也在进行针对1型糖尿病患者的2期临床研究。 ③达佐利单抗(Dazodalibep)：一种非抗体生物拮抗剂，由两个能结合CD40L的Tn3蛋白与人血清白蛋白融合而成，在RA的Ⅱ期临床试验中，显著降低了疾病活动度，且不良事件与安慰剂组相当，耐受性良好。 ④Abiprubart：一种CD40拮抗单克隆抗体，可阻断CD40-CD40L相互作用介导的B细胞激活，在RA的Ⅱ期试验中达到了主要终点。 ⑤Ravagalimab：一种CD40拮抗剂单克隆抗体，在UC的Ⅱ期试验中进行了测试。 ● 临床意义 CD40/CD40L通路的过度激活与多种自身免疫性疾病相关，如SLE患者血清中可溶性CD40L水平升高，且与疾病活动度密切相关；RA患者血清中CD40表达水平上升，与ACPA增加及疾病活动度显著相关。CD40/CD40L拮抗剂通过抑制该通路，有助于减少炎症介质释放，调节免疫细胞功能，延缓关节损伤进展，为自身免疫性疾病患者提供了新的治疗选择。在SLE治疗中，可降低自身抗体滴度，减少疾病发作；在RA治疗中，能改善疾病活动度；在MS治疗中，可减少大脑病变，降低组织损伤。 ● 面临挑战早期CD40L抗体在临床试验中出现过血栓栓塞并发症，这是由于抗体对CD40L和血小板上的Fc受体(FcRs)双重结合，导致血小板激活引发。不过，后续开发的Fc沉默或缺乏Fc结构域的CD40/CD40L拮抗剂，如Frexalimab、Dapirolizumab-pegol等，在安全性方面有了明显改善，在临床试验中未显示出血栓栓塞活动迹象。此外，自身免疫性疾病具有异质性，部分由T细胞独立机制驱动的疾病，对抗CD40L治疗可能反应不佳。 OX40/OX40L拮抗剂 ● 作用机制：OX40/OX40L拮抗剂可抑制二者的结合，阻断上述信号通路的激活，进而降低炎症反应和免疫应答强度。比如靶向OX40的单克隆抗体可抑制和减少表达OX40的活化T细胞数量；靶向OX40L的单克隆抗体不耗竭已活化T细胞，而是通过与OX40L结合，阻止其与OX40相互作用，阻断T细胞活化。 ● 研发进展 ①罗卡替尼(Rocatinlimab)：一种全人源、IgG1型抗OX40单克隆抗体，通过抑制OX40，抑制T细胞增殖、扩增和记忆T细胞形成。通过抗体依赖的细胞毒性(ADCC)清除OX40+T细胞，在特应性皮炎中使湿疹面积和严重程度指数(EASI)降低50%以上。 ②阿美利单抗(Amlitelimab)：一种非T细胞耗竭、全人源的IgG4型抗OX40L单克隆抗体，可与OX40L结合，阻断其与OX40的相互作用，还可抑制OX40L的反向信号传导，阻断2型和Th1/17/22炎症。 ● 临床意义 OX40/OX40L信号通路的异常激活与多种自身免疫性疾病相关，如在AD患者的皮肤中，OX40/OX40L表达上调，促进IL-4驱动的Th2辅助细胞分化。OX40/OX40L拮抗剂通过抑制该通路，有助于减少炎症介质释放，调节免疫细胞功能，为自身免疫性疾病患者提供了新的治疗选择。在AD治疗中，可改善皮肤症状，如降低湿疹面积和严重程度指数，清除或减轻皮肤症状。 ● 面临挑战作为TNFR超家族成员，OX40靶点抗体存在一定风险，这类抗体如果引起靶点交联，会短时内极大地激活T细胞，引起细胞因子释放综合征，严重时危及生命。因此，筛选具有阻断活性而非激动活性的抗体、降低体内交联风险、开展试验充分评估风险等，是确保OX40拮抗剂未来长期安全性的重点与难点。 BAFF/BAFF-R拮抗剂 ● 作用机制：BAFF/BAFF-R拮抗剂通过阻断BAFF与BAFF-R的相互作用，抑制这些信号通路的激活，减少B细胞的活化和自身抗体的分泌，进而减轻自身免疫反应。 ● 研发进展 ①贝利尤单抗(Benlysta，2011年获批)：首个获批用于SLE治疗的抗BAFF单克隆抗体，能抑制B细胞存活和分化为浆细胞，降低患者血清IgG和自身抗体水平。 ②泰它西普(Telitacicept，中国获批)：一种能中和BAFF和增殖诱导配体(APRIL)的Fc融合蛋白，用于SLE和IgA肾病，减少蛋白尿和肾功能损伤。 ③Ianalumab：一种BAFF-R拮抗的人IgG1单克隆抗体，通过ADCC作用裂解B细胞并阻断BAFF-R信号，在SLE的Ⅱ期研究中表现良好，降低了疾病活动度和自身抗体滴度，目前正在进行Ⅲ期研究。 ④Rozibafuspalfa：一种同时拮抗BAFF和诱导性T细胞共刺激配体(ICOSL)的双特异性抗体，正在进行SLE的Ⅱb期研究。 ⑤Povetacicept：一种与TACI融合的Fc蛋白，可中和BAFF和APRIL，已进入自身免疫性肾脏疾病的Ib/2a期研究。 ● 临床意义 BAFF/BAFF-R信号通路在SLE、RA等自身免疫性疾病的发病机制中起关键作用。SLE患者血清BAFF水平与疾病活动度和自身抗体水平相关，RA患者滑膜组织中BAFF-R表达升高。BAFF/BAFF-R拮抗剂为这些疾病的治疗提供了新方向，能有效减少自身抗体和免疫复合物的产生，缓解系统性炎症和组织损伤。在SLE治疗中，可降低疾病活动度，改善肾脏等器官功能；在RA治疗中，有望减轻关节炎症和损伤。 ● 面临挑战尽管BAFF/BAFF-R拮抗剂在临床试验中取得了一定成果，但仍面临一些挑战。部分患者对药物的应答存在差异，并非所有患者都能获得理想的治疗效果。长期使用这些拮抗剂可能会影响正常的B细胞功能，增加感染等不良反应的风险。此外，药物的研发和生产成本较高，可能限制其广泛应用。表2 靶向TNF/TNFR的药物(2 期及以上) 表3 TNFS 或TNFRSF在自身免疫和炎症中的临床靶向 04 其他潜在靶点图5 其他FDA批准的基于TNFSF的疗法 CD30/CD30L ● 机制：CD30与CD30L的信号传导是活化T细胞和专职抗原呈递细胞(APCs)的主要促存活和促炎信号。 ● 疾病关联：CD30在类风湿关节炎(RA)、系统性红斑狼疮(SLE)、特应性皮炎(AD)和哮喘等多种IMIDs中表达上调，其基因多态性与湿疹相关。 ● 研发进展： ①MK-8690(PRA-052)：一种人抗CD30L单克隆抗体，目前处于Ⅰ期临床试验阶段，用于炎症性肠病(IBD)治疗，旨在评估其安全性和药理学特性。 4-1BB(TNFRSF9) ● 机制：4-1BB在活化T细胞上表达，其共信号作用可促进T细胞存活、增殖和细胞因子产生。 ● 潜在应用：虽然4-1BB激动剂主要用于癌症治疗，但基于其在免疫调节中的作用，研究探索了通过4-1BB选择性“同种免疫防御受体”(ADR)设计细胞疗法，以选择性清除致病性淋巴细胞，在自身免疫病和移植物抗宿主病(GvHD)中诱导免疫耐受，相关临床前研究已显示潜力。图6 结合4-1BB信号传导的免疫治疗策略 RANK/RANKL ● 机制：成骨细胞表达的膜结合RANKL与RANK结合，通过相互作用调控髓系细胞分化为破骨细胞，是骨吸收和稳态的主要驱动因素。 ● 疾病关联：在RA中，RANK/RANKL信号与骨侵蚀密切相关。 ● 研发进展： ①地诺单抗(Denosumab，2010年获批)：抗RANKL单克隆抗体，用于骨质疏松症等治疗，在日本还被批准用于抑制RA相关的骨侵蚀。Ⅲ期研究显示，其能显著减少RA患者的关节破坏进展。 BCMA(TNFRSF17) ● 机制：BAFF和APRIL与BCMA结合，驱动浆细胞存活，BCMA在成熟B细胞(尤其是长寿骨髓浆细胞和浆母细胞)上高表达。 ● 疾病关联：与SLE等自身免疫病中自身抗体的产生相关。 ● 研发进展： ①Descartes-08(RNA-based自体BCMA特异性CAR-T)：用于SLE治疗，处于Ⅱ期评估阶段； ②CD19-BCMA双靶点CAR-T疗法：在狼疮性肾炎(LN)患者的Ⅰ期研究中显示出显著疗效，可清除自身抗体并实现症状缓解。图7 治疗癌症的新型TNFRSF疗法表4 TNFRSF在癌症中的临床靶向抗体发现服务 & 产品 01 羊驼免疫&骆驼免疫—自建现代化养殖农场 02 万亿级天然抗体库产品—轻松DIY科研抗体 03 配套产品—助您轻松搭建基因工程抗体平台关于仁域生物成都仁域生物成立于2019年1月，是一家专注基因工程抗体技术和天然抗体库开发的公司，拥有优化的噬菌体展示抗体库技术和现代化的骆驼/羊驼养殖免疫基地。公司主营业务： ◆ 全人源/纳米抗体定制；◆ 噬菌体展示抗体库定制； ◆ 多肽/多肽库定制；◆ 羊驼/骆驼免疫服务； ◆ 文库相关产品经销商。 protocol 获取 / 产品咨询邮箱｜find@renyubio.com 电话｜19136178673 地址｜成都市经开区科技产业孵化园关注我们，小编将持续更新相关内容～参考文献 Watts TH, Yeung KKM, Yu T, Lee S, Eshraghisamani R. TNF/TNFR Superfamily Members in Costimulation of T Cell Responses-Revisited. Annu Rev Immunol. 2025 Apr;43(1):113-142. Croft M, Salek-Ardakani S, Ware CF. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov. 2024 Dec;23(12):939-961. Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases. J Exp Med. 2024 Nov 4;221(11):e20240806. Müller D. Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy. BioDrugs. 2023 Jan;37(1):21-33.

蛋白降解靶向嵌合体免疫疗法临床终止

2025-09-03

·PRNewswire

BioFactura Launches Capitol Biologics - New CDMO Division to Accelerate Biologics Development from Concept to Clinic

FREDERICK, Md., Sept. 3, 2025 /PRNewswire/ -- BioFactura, Inc., a clinical‑stage biopharmaceutical company specializing in high‑value biosimilars and critical biodefense medical countermeasures, today announced the formation of Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division dedicated to supporting the process development, early‑phase clinical manufacturing, and analytical needs of emerging biotechnology companies and U.S. government agencies. Strategically located in the BioHealth Capital Region, Capitol Biologics combines technical excellence, regulatory expertise, and personalized collaboration to advance innovative biologics from lab bench to first‑in‑human studies. Building on BioFactura's two decades of expertise in biologics development, Capitol Biologics will deliver full‑service, phase‑appropriate manufacturing solutions for monoclonal antibodies, recombinant proteins, and other complex biologics. The division combines advanced cell line development, upstream and downstream process optimization, GMP manufacturing, and extensive analytical and quality control capabilities under a unified quality management system aligned to global regulatory standards (FDA, EMA, ICH). Located in the greater Washington, DC metropolitan area—within the BioHealth Capital Region and the I‑270 Biotech Corridor—Capitol Biologics is strategically positioned to provide streamlined logistical access to major pharmaceutical hubs, government facilities, and world‑class research institutions. The division will support both private‑sector biotech innovators and public health initiatives aimed at strengthening national preparedness. President and CEO Darryl Sampey stated, "Transforming the biopharma development engine that BioFactura has built over the past 20 years into a pure-play service organization provides an incomparable value to early-stage ventures and initiatives. The depth of experience, know-how and capability that we have gained saves our clients both time and money that are in many cases existential to their survival and success." "Capitol Biologics represents the next evolution of BioFactura's mission," said Dr. Jeffrey Hausfeld, M.D., M.B.A., F.A.C.S., Chairman of the Board and Chief Medical Officer of BioFactura. "We are combining our proven technical excellence in biologics development with a personalized, collaborative service model for our clients. Our goal is to help innovators advance their therapies to clinical reality faster, more efficiently, and with the highest quality standards. This new division allows us to share our expertise, infrastructure, and passion for science with the broader biotech community at a critical stage of their growth." As entrepreneurs ourselves, we understand the needs of our clients. Our goal is to be "Fit For Purpose"! By our nature, we are problem solvers. Our aim is to efficiently deliver what our client's need, when they need it. Capitol Biologics' culture of innovation and entrepreneurship offers a unique personalized experience that aligns with our client's motivations and needs, eliminates unnecessary friction, and addresses the real-world concerns that companies face every day. Our mission is to get our clients from concept to clinic…. seamlessly! About BioFactura, Inc. Founded in 2004, BioFactura develops and manufactures high‑value biosimilars and biodefense medical countermeasures using its proprietary StableFast™ Biomanufacturing Platform. The company's pipeline includes biosimilar candidates referencing products such as Stelara® and Simponi® as well as a novel smallpox therapeutic. About Capitol Biologics Capitol Biologics, a division of BioFactura, Inc., is a full‑service Contract Development and Manufacturing Organization (CDMO) focused on early‑phase clinical biologics manufacturing. Capitol Biologics' integrated capabilities span cell line development, process development, GMP manufacturing, comprehensive analytical services and clinical trial support. With a strategic location in Frederick, Maryland, and a commitment to quality, innovation, and client collaboration, Capitol Biologics guides products seamlessly from concept to clinic SOURCE BioFactura WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-08-22

·PRNewswire

Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the interleukin-6 receptor, indicated for the treatment of multiple inflammatory and autoimmune disorders Bio-Thera will have responsibility for development, manufacturing, and supply of the biosimilar to Roche's RoActemra ® reference brand STADA will have exclusive rights to commercialize the product in the EU, the UK, Switzerland and selected other countries under its own marketing authorization GUANGZHOU, China and BAD VILBEL, Germany, Aug. 22, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have agreed to extend their biosimilars alliance to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The effectiveness of the agreement covering tocilizumab is subject to shareholder approval. Continue Reading Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab Bio-Thera will maintain responsibility for development, manufacturing, and supply of the tocilizumab biosimilar to Roche's RoActemra ® reference brand. STADA, including its affiliates, will have exclusive rights to commercialize the biosimilar in the European Union (EU), the UK, Switzerland and selected other countries under its own marketing authorization. This agreement for tocilizumab builds upon an existing partnership on similar terms for BAT2506, a biosimilar candidate to Simponi ® (golimumab), that the two companies announced in May 20241. A marketing authorization application (MAA) for BAT2506 has subsequently been accepted by the European Medicines Agency (EMA). "Benefiting from a proven track record in immunology, STADA ranks among the premier biosimilar companies in Europe," said Dr. Shengfeng Li, CEO of Bio-Thera. "We look forward to extending our partnership to bring biosimilar tocilizumab to patients in Europe." "With global RoActemra/Actemra sales in 2024 reported at approximately €2.8 billion, including around US$700 million in Europe despite the advent of biosimilar competition, tocilizumab represents a compelling opportunity to broaden patient access to biological treatments and build scale in immunology alongside our approved adalimumab and ustekinumab biosimilars that hold leading positions in several European countries. Bio-Thera's expertise in developing and manufacturing biologic medicines makes it an appealing partner for STADA," commented STADA's head of Global Specialty, Ian Henshaw. In June 2024, tocilizumab 20mg/ml concentrate for solution developed by Bio-Thera under the BAT1806 code received a marketing authorization for the vials that is valid throughout the EU2. This followed a positive opinion issued by the European Medicines Agency that the biosimilar to Roche's RoActemra reference brand be approved as a medicine to treat several arthritic conditions. 1 Bio-Thera Solutions, Ltd.,; Bio-Thera and STADA Reach Exclusive Agreement for BAT2506 | STADA 2 Union Register of medicinal products - Public health - European Commission About Bio-Thera Solutions Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including five approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US and Usymro®(ustekinumab) in EU, and BAT1806/TOFIDENCE™ (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and in EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit or follow us on X( @bio_thera_soln) and WeChat (Bio-Thera). About STADA Arzneimittel AG STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group revenues of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide. Bio-Thera Cautionary Note Regarding Forward-Looking Statements This news release contains certain forward-looking statements relating to BAT1806, or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing "could," "may," "should," "will," "would," "anticipate," "believe," "plan," "promising," "potentially," or similar expressions. They reflect the company's current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company's financial conditions, and changes to applicable laws and regulations, Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company's views or otherwise. Bio-Thera Contact for additional information: Bert E. Thomas IV Phone: +1.410.627.1734 Email: [email protected] STADA information for journalists: STADA Arzneimittel AG - Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany Phone: +49 (0) 6101 603-165 E-Mail: [email protected] Or visit us on the Internet at Follow @STADAGroup on LinkedIn STADA information for capital market participants: STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18 61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: [email protected] Or visit us on the Internet at SOURCE Bio-Thera Solutions, Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出上市批准

100 项与戈利木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04358	戈利木单抗	L04AB06	DB06674

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
中轴性脊柱关节炎	欧盟	Janssen Biologics BV	2009-10-01
中轴性脊柱关节炎	冰岛	Janssen Biologics BV	2009-10-01
中轴性脊柱关节炎	列支敦士登	Janssen Biologics BV	2009-10-01
中轴性脊柱关节炎	挪威	Janssen Biologics BV	2009-10-01
溃疡性结肠炎	欧盟	Janssen Biologics BV	2009-10-01
溃疡性结肠炎	冰岛	Janssen Biologics BV	2009-10-01
溃疡性结肠炎	列支敦士登	Janssen Biologics BV	2009-10-01
溃疡性结肠炎	挪威	Janssen Biologics BV	2009-10-01
幼年特发性关节炎	欧盟	Janssen Biologics BV	2009-10-01
幼年特发性关节炎	冰岛	Janssen Biologics BV	2009-10-01
幼年特发性关节炎	列支敦士登	Janssen Biologics BV	2009-10-01
幼年特发性关节炎	挪威	Janssen Biologics BV	2009-10-01
非放射性轴性脊柱关节炎	欧盟	Janssen Biologics BV	2009-10-01
非放射性轴性脊柱关节炎	冰岛	Janssen Biologics BV	2009-10-01
非放射性轴性脊柱关节炎	列支敦士登	Janssen Biologics BV	2009-10-01
非放射性轴性脊柱关节炎	挪威	Janssen Biologics BV	2009-10-01
多关节型幼年特发性关节炎	欧盟	Janssen Biologics BV	2009-10-01
多关节型幼年特发性关节炎	冰岛	Janssen Biologics BV	2009-10-01
多关节型幼年特发性关节炎	列支敦士登	Janssen Biologics BV	2009-10-01
多关节型幼年特发性关节炎	挪威	Janssen Biologics BV	2009-10-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
炎症	临床3期	比利时	Merck Sharp & Dohme Corp.	2017-11-08
涎腺多形性腺瘤	临床3期	英国	Janssen Pharmaceutica NV	2015-10-27
附着点炎	临床3期	葡萄牙	Merck Sharp & Dohme LLC	2014-08-01
脊椎关节炎	临床3期	比利时	Janssen Biologics BV	2012-03-13
多发性关节炎	临床3期	美国	Janssen Research & Development LLC	2010-12-01
多发性关节炎	临床3期	美国	Schering-Plough Corp.	2010-12-01
多发性关节炎	临床3期	奥地利	Janssen Research & Development LLC	2010-12-01
多发性关节炎	临床3期	奥地利	Schering-Plough Corp.	2010-12-01
多发性关节炎	临床3期	比利时	Janssen Research & Development LLC	2010-12-01
多发性关节炎	临床3期	比利时	Schering-Plough Corp.	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03729349 (Pubmed \| Patient Prefer Adherence)	N/A	类风湿关节炎	215	High adherence to golimumab treatment	壓獵構簾鬱構醖築餘膚(憲構廠鹹範範壓廠膚繭) = 鹽顧鬱鏇網襯鬱廠齋艱衊繭製齋製襯築窪襯構 (製鹽鹹遞壓糧築鬱選淵 ) 更多	不佳	2025-06-01
				Low adherence to golimumab treatment	壓獵構簾鬱構醖築餘膚(憲構廠鹹範範壓廠膚繭) = 範鹽窪獵廠齋膚餘構遞衊繭製齋製襯築窪襯構 (製鹽鹹遞壓糧築鬱選淵 ) 更多
NCT03270501 (GO-GUT, CTgov)	临床3期	炎症 \| 中轴性脊柱关节炎	64	Golimumab	廠廠壓鬱襯餘齋顧窪膚 = 範鹹製糧鏇鬱醖選遞範觸鬱廠憲獵鑰顧窪廠網 (網鑰襯鬱艱獵鹹簾簾壓, 襯齋網淵餘醖糧觸鑰鏇 ~ 網壓鑰窪窪獵廠膚壓鬱) 更多	-	2025-02-11
NCT05842213 (ALVOFLEX, ACR2024 \| NEWS)	-	类风湿关节炎	502	戈利木单抗-AVT05	簾觸鹽淵衊夢製襯觸衊(淵膚餘獵糧鏇醖膚遞願) = Clinical results have reached the endpoint 醖窪網製鬱構鏇齋衊鏇 (淵顧觸選衊廠遞遞範窪 )	相似	2024-04-24
				戈利木单抗
NCT02277444 (GO-VIVA, ACR2023)	临床3期	多关节型幼年特发性关节炎	127	Golimumab 80 mg/m2 IV q8w	遞夢遞製簾艱願鏇淵築(遞壓鬱網鏇願選築齋遞) = AEs and SAEs were reported in 92.1% and 19.7% of pts, respectively. One death (septic shock) occurred. 築製遞簾艱糧積鹹糧顧 (獵糧齋繭網觸鏇廠選壓 )	积极	2023-11-12
				Placebo
NCT00488631 (PURSUIT-M, Pubmed \| Crohns Colitis 360)	临床3期	活动性重度溃疡性结肠炎维持	1,228	Golimumab 50 mg	製製觸夢製衊積鏇衊網(窪顧糧鏇鹽範積簾齋鬱) = 廠鏇窪鹹範夢鹹遞網憲獵窪製醖淵壓齋衊餘製 (遞顧艱鏇蓋簾顧淵夢製 )	积极	2023-07-01
				Golimumab 100 mg	製製觸夢製衊積鏇衊網(窪顧糧鏇鹽範積簾齋鬱) = 壓襯衊糧鑰齋餘憲壓廠獵窪製醖淵壓齋衊餘製 (遞顧艱鏇蓋簾顧淵夢製 )
BIOBADABRASIL (EULAR2023)	N/A	类风湿关节炎	227	Certolizumab	顧築淵製繭繭壓壓鹹窪(鏇淵襯繭獵積餘簾鑰艱): hazard ratio = 1.58 (95% CI, 0.96 ~ 2.6), P-Value = 0.069	不佳	2023-05-31
				Golimumab
NCT02728934 (Pubmed)	临床4期	类风湿关节炎	1,270	IV golimumab	壓蓋選積鏇糧淵蓋範蓋(壓遞獵壓顧觸膚壓艱壓) = 鹽襯窪鑰構鏇夢醖觸積獵構鬱獵製鑰廠憲鹽艱 (選鏇齋廠糧繭積簾構蓋 ) 更多	-	2023-02-23
				Infliximab	壓蓋選積鏇糧淵蓋範蓋(壓遞獵壓顧觸膚壓艱壓) = 積範鹹淵齋醖製構憲觸獵構鬱獵製鑰廠憲鹽艱 (選鏇齋廠糧繭積簾構蓋 ) 更多
NCT03733925 (CTgov)	临床4期	银屑病关节炎 \| 强直性脊柱炎	100	Golimumab (Simponi)	淵選壓選鏇齋廠製範遞 = 網醖淵膚觸廠膚淵憲廠獵選壓繭製憲遞艱鹹襯 (淵鹽糧醖獵鏇衊構憲網, 夢鬱窪獵淵夢糧獵積糧 ~ 鬱憲積糧鏇鏇觸願鹽獵) 更多	-	2023-01-20
BiKeR registry (ACR2022)	N/A	多关节型幼年特发性关节炎	-	Golimumab	鏇糧選獵選繭壓鬱醖構(膚齋構夢廠製簾夢繭遞) = p=0.03 by χ2-test 鹹艱廠窪獵鏇鏇衊製願 (蓋範糧蓋觸窪鹽鏇鹽壓 ) 更多	积极	2022-11-13
ACR2022	N/A	银屑病关节炎 \| 类风湿关节炎 \| 中轴性脊柱关节炎	-	Golimumab	願鹹夢遞衊獵淵齋鏇齋(構獵衊淵淵範獵鬱範蓋) = 壓膚製壓醖衊齋築鑰窪製鹽構積願築鏇範膚觸 (醖觸範壓獵襯願簾憲繭 ) 更多	-	2022-11-13